



**Dr. Reddy's Laboratories Ltd.**  
8-2-337, Road No. 3, Banjara Hills  
Hyderabad – 500 034, Telangana, India  
CIN: L85195TG1984PLC004507  
Tel: + 91 40 4900 2900  
Fax: + 91 40 4900 2999  
Email: [mail@drreddys.com](mailto:mail@drreddys.com)  
Web: [www.drreddys.com](http://www.drreddys.com)

January 1, 2026

National Stock Exchange of India Ltd. (Scrip Code: DRREDDY)

BSE Limited (Scrip Code: 500124)

New York Stock Exchange Inc. (Stock Code: RDY)

NSE IFSC Ltd. (Stock Code: DRREDDY)

Dear Sir/Madam,

**Ref: Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015**

This is to inform that the Company has received five separate orders from GST Authority towards tax demand including interest and levying penalty for the period FY 2018-19 to FY 2022-23. The details as required under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 are as hereunder:

S.No.	Name of the authority	:	Joint Commissioner, Office of Principal Commissioner of Central Tax, Visakhapatnam												
1	Nature and details of the action(s) taken, or order(s) passed	:	The Company has received such orders seeking demand including interest and levying penalty under APGST Act 2017.												
2	Date of receipt of direction or order, including any ad-interim or interim orders, or any other communication from the authority	:	Orders dated December 31, 2025, were received by the Company on December 31, 2025.												
3	Details of the violation(s)/contravention(s) committed or alleged to be committed	:	The authority has passed the orders on the ground that the Company has availed excess input tax credit.												
4	Impact on financial, operation or other activities of the listed entity, quantifiable in monetary terms to the extent possible	:	<p>The above orders levy penalty as detailed below:</p> <table border="1"><thead><tr><th>Financial Year</th><th>Penalty (INR)</th></tr></thead><tbody><tr><td>FY 2018-19</td><td>1,89,30,110</td></tr><tr><td>FY 2019-20</td><td>80,41,186</td></tr><tr><td>FY 2020-21</td><td>3,52,95,063</td></tr><tr><td>FY 2021-22</td><td>1,45,04,023</td></tr><tr><td>FY 2022-23</td><td>70,86,675</td></tr></tbody></table> <p>Based on our evaluation, there is no material impact on the financials, operations, or other activities of the Company.</p>	Financial Year	Penalty (INR)	FY 2018-19	1,89,30,110	FY 2019-20	80,41,186	FY 2020-21	3,52,95,063	FY 2021-22	1,45,04,023	FY 2022-23	70,86,675
Financial Year	Penalty (INR)														
FY 2018-19	1,89,30,110														
FY 2019-20	80,41,186														
FY 2020-21	3,52,95,063														
FY 2021-22	1,45,04,023														
FY 2022-23	70,86,675														

The Company will evaluate filing necessary appeal with the appellate authority in this regard.

This is for your information and records.

Thanking you,

Yours faithfully,

**For Dr. Reddy's Laboratories Limited**

**K Randhir Singh**

*Company Secretary, Compliance Officer & Head-CSR*